Takeda Pharmaceutical Company Limited: shareholders and insiders

TAKNYSEHealthcare · Pharmaceutical Preparations

Price

$21.41

November 19, 2026

What Ploutos Investor adds for Takeda Pharmaceutical

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from FY2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Jul 1, 2026 to Nov 5, 2026, from their own Form 4 filings.

45 Form 4s

Bought on the market

–

nobody

Sold on the market

$15M

13 people

From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan16%
  • The rest84%
  • Nov 4, 2026Giles Richard PlatfordPresident, IBU
    Kind
  • Nov 2, 2026Teresa Marie BitettiPresident, OBU
    Kind
  • Sep 14, 2026Lauren Rusckowski DupreyChief Transformation Officer
    Kind
  • Sep 2, 2026Andrew Stewart PlumpPresident, R&D
    Kind10b5-1
  • Aug 19, 2026Andrew Stewart PlumpPresident, R&D
    Kind10b5-1
  • Aug 18, 2026Nicola Deidre Petal GreenwayChief Human Resources Officer
    Kind
  • Aug 11, 2026Elaine Mary ShannonPres., Global Supply & Quality
    Kind
  • Aug 10, 2026Awny Samaan Botros FarajallahChief Medical Officer
    Kind
  • Aug 10, 2026Ramy Riad Ahmed IbrahimPresident, PDT BU
    Kind
  • Aug 10, 2026Rhonda Janice PachecoPresident, U.S. Business Unit
    Kind
  • Aug 10, 2026Lauren Rusckowski DupreyChief Transformation Officer
    Kind
  • Aug 10, 2026Andrew Stewart PlumpPresident, R&D
    Kind
  • Aug 10, 2026Agosti Marcello PignagnoliHead, Strat. & Port. Dev
    Kind
  • Aug 10, 2026Teresa Marie BitettiPresident, OBU
    Kind
  • Aug 10, 2026Elaine Mary ShannonPres., Global Supply & Quality
    Kind
  • Aug 10, 2026Gabriele RicciChief Data & Tech. Officer
    Kind
  • Aug 10, 2026Nicola Deidre Petal GreenwayChief Human Resources Officer
    Kind
  • Aug 10, 2026Julie So-Young KimPresident and CEO
    Kind
  • Aug 10, 2026Giles Richard PlatfordPresident, IBU
    Kind
  • Aug 10, 2026Natalie Anne Marie FurneyGlobal General Counsel
    Kind
  • Aug 10, 2026Nicola Deidre Petal GreenwayChief Human Resources Officer
    Kind
  • Aug 10, 2026Nicola Deidre Petal GreenwayChief Human Resources Officer
    Kind
  • Jul 1, 2026Steven GillisDirector
    Kind
  • Jul 1, 2026John MaraganoreDirector
    Kind
  • Jul 1, 2026Kimberly A. ReedDirector
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

No filing over 5%

Since Dec 18, 2024 nobody has filed a Schedule 13D or 13G for Takeda Pharmaceutical shares.

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Renaissance Technologies
    In the quarter-11%
  • D.E. Shaw
    In the quarter+53%
  • Millennium Mgmt (Englander)
    In the quarter+27%
  • Point72 (Cohen)
    In the quarter+445%
  • Citadel Advisors (Griffin)
    In the quarter+375%
  • AQR Capital
    In the quarter+1.4%
  • Bridgewater (Dalio)
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short sales in daily trading

How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.

46.4% the last 14 sessions+12.5 pts vs the 14 before

In the last 14 sessions, 46.4% of the shares in the reported trades were short sales, against 33.9% in the 14 before.

Last 14 sessionsNov 2, 2026 – Nov 19, 2026
46.4%
The 14 beforeOct 13, 2026 – Oct 30, 2026
33.9%
Change
+12.5 pts
Short sales a dayon average, of 1.44M shares
666.3K
More than atof 3,666 US-listed companies, same days
36%
Median of alleight in ten from 34.5% to 63.8%
50.4%
  • Oct 13, 2026: Short sales 30.9%
  • Oct 14, 2026: Short sales 37.4%
  • Oct 15, 2026: Short sales 25.9%
  • Oct 16, 2026: Short sales 26%
  • Oct 19, 2026: Short sales 33.8%
  • Oct 20, 2026: Short sales 29.5%
  • Oct 21, 2026: Short sales 26.4%
  • Oct 22, 2026: Short sales 25.5%
  • Oct 23, 2026: Short sales 30%
  • Oct 26, 2026: Short sales 36%
  • Oct 27, 2026: Short sales 36.3%
  • Oct 28, 2026: Short sales 38.8%
  • Oct 29, 2026: Short sales 42.4%
  • Oct 30, 2026: Short sales 48.5%
  • Nov 2, 2026: Short sales 37.8%
  • Nov 3, 2026: Short sales 44%
  • Nov 4, 2026: Short sales 47.1%
  • Nov 5, 2026: Short sales 51.2%
  • Nov 6, 2026: Short sales 52.2%
  • Nov 9, 2026: Short sales 43.8%
  • Nov 10, 2026: Short sales 45.6%
  • Nov 11, 2026: Short sales 33.5%
  • Nov 12, 2026: Short sales 37.7%
  • Nov 13, 2026: Short sales 59.9%
  • Nov 16, 2026: Short sales 53.9%
  • Nov 17, 2026: Short sales 44%
  • Nov 18, 2026: Short sales 45.5%
  • Nov 19, 2026: Short sales 48.8%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

3.21M Insiders' shares0.21% Of the company
  • Andrew Stewart PlumpPresident, R&D
    Directly912.0K
  • Julie So-Young KimPresident and CEO
    Directly391.5K
  • Giles Richard PlatfordPresident, IBU
    Directly270.3K
  • Teresa Marie BitettiPresident, OBU
    Directly214.5K
  • Natalie Anne Marie FurneyGlobal General Counsel
    Directly204.3K
  • Lauren Rusckowski DupreyChief Transformation Officer
    Directly191.5K
  • Rhonda Janice PachecoPresident, U.S. Business Unit
    Directly182.5K
  • Agosti Marcello PignagnoliHead, Strat. & Port. Dev
    Directly177.0K
  • Gabriele RicciChief Data & Tech. Officer
    Directly171.7K
  • Awny Samaan Botros FarajallahChief Medical Officer
    Directly116.2K
  • Ramy Riad Ahmed IbrahimPresident, PDT BU
    Directly102.6K
  • Milano FurutaChief Financial Officer
    Directly70.2K
  • Elaine Mary ShannonPres., Global Supply & Quality
    Directly63.3K
  • Nicola Deidre Petal GreenwayChief Human Resources Officer
    Directly40.0K
  • Steven GillisDirector
    Directly22.1K
  • Jennifer Marie SmoterChief Comm. & Gov. Officer
    Directly18.8K
  • Kimberly A. ReedDirector
    Directly15.2K
  • Masami IijimaDirector
    Directly14.6K
  • John MaraganoreDirector
    Directly13.8K
  • Miki TsusakaDirector
    Directly8,200
  • Bruce D BroussardDirector
    Directly4,595
  • Asuka MiyabashiraPresident, Japan Pharma B.U.
    Directly4,500
  • Paulus StoffelsDirector
    Directly3,800
  • Koichiro KimuraDirector
    Directly1,800

A lower bound: it counts only the 24 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

35 ETFs holding it2.87% The largest weight (PPH)
  • PPHVanEck Pharmaceutical ETF
    Weight in the fund2.87%
  • DXJWisdomTree Japan Hedged Equity Fund
    Weight in the fund1.65%
  • EFAViShares MSCI EAFE Min Vol Factor ETF
    Weight in the fund1.41%
  • EWJiShares MSCI Japan ETF
    Weight in the fund1.09%
  • BBJPJPMorgan BetaBuilders Japan ETF
    Weight in the fund0.99%
  • FLJPFranklin FTSE Japan ETF
    Weight in the fund0.80%
  • IXJiShares Global Healthcare ETF
    Weight in the fund0.66%
  • DFIVDimensional International Value ETF
    Weight in the fund0.58%
  • JIREJPMorgan International Research Enhanced Equity ETF
    Weight in the fund0.49%
  • VPLVanguard Pacific Stock Index Fund
    Weight in the fund0.45%

35 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

376 Managers, Q2 2026$1.7B Value of their positions
  • Q3 2025: Managers 330
  • Q4 2025: Managers 351
  • Q1 2026: Managers 362
  • Q2 2026: Managers 376

Institutional investors by quarter

The fund managers holding TAK, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 376 managers held 104M shares, worth $1.7B. During the quarter 67 opened a position, 53 closed one, 142 added and 100 trimmed.

The largest holders, Q2 2026

  • Capital Research Global Investors
    In the quarter+1.0%
  • FMR
    In the quarter+35%
  • Morgan Stanley
    In the quarter+8.1%
  • Adage Capital Partners Gp
    In the quarter-5.8%
  • Goldman Sachs Group
    In the quarter-8.8%
  • Brandes Investment Partners
    In the quarter+2.5%
  • Arrowstreet Capital, Limited Partnership
    In the quarter+20%
  • BlackRock
    In the quarter+16%
  • Renaissance Technologies
    In the quarter-14%
  • Qube Research & Technologies
    In the quarter

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Takeda Pharmaceutical's filings show?

Who buys and sells is one part of Takeda Pharmaceutical's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about TAK's shareholders

Didn't find what you were looking for?

Ask us
Have TAK's insiders bought or sold?

From Jul 6, 2026 to Nov 5, 2026 Takeda Pharmaceutical's insiders bought 0 and sold $15M of shares on the market. 16% of the sales were under set 10b5-1 plans.

Which well-known managers hold TAK?

7 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $57M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.